University of Wisconsin Supports DiscoveryGate® Content Platform for North American Academic Consortia
Minerva Host to offer full technical support to consortium members licensing DiscoveryGate
San Ramon, CA – November 29, 2006 – Elsevier MDL is pleased to announce that the University of Wisconsin will provide full technical support to all members of the North American MINERVA consortium that license either the full DiscoveryGate® content platform or the Beilstein and/or Gmelin databases using the DiscoveryGate platform. The University of Wisconsin currently hosts the MINERVA and MENTOR programs that provide students, faculty and researchers at over 100 North American universities with unlimited access to their respective licensed databases, including CrossFire Beilstein, Crossfire Gmelin and MDL® ISIS chemical sourcing, bioactivity and synthetic methodology databases.
"The University of Wisconsin is pleased to expand our role with the academic, scientific research and library communities by supporting DiscoveryGate from Elsevier MDL," said Nolan Pope, Associate Director for Technology, General Library System, UW-Madison. "Extending technical and user support to the DiscoveryGate platform enables the growing number of North American universities to benefit from this important chemistry and life science resource."
DiscoveryGate serves tens of thousands of eligible users at more than 400 commercial, academic and government institutions worldwide and is supported on both the Microsoft Windows® and Apple Macintosh® OS X platforms. Because DiscoveryGate is widely deployed in the commercial research environment, hands-on experience with DiscoveryGate in the university setting will prepare students for success in today's highly competitive job market.
DiscoveryGate's unique integration and linking of content enables researchers to compare information and results that are not available through other systems. With the indexing of important new data sources this year (e.g., PharmaPendium™ drug safety resource, PubChem® database, GeneGo systems biology/pathway analysis platform, etc.), DiscoveryGate now provides detailed scientific information on more than 22 million chemical compounds, 11 million reactions and 500 million observed chemical facts, including synthesis, bioactivity, metabolism, toxicology, physical property, chemical sourcing, pharmacology and patent data—all from a single query.
Researchers can access 17 databases including the Beilstein and Gmelin databases (which are also available on the CrossFire system from MDL Information Systems GmbH), MDL® Available Chemicals Directory, MDL® Drug Data Report, MDL® Toxicity Database and authoritative reference works on synthetic methodology. Researchers can also search compounds in PubChem and the Derwent World Patents Index®, and they can link to over 20,000 journal titles (with additional licenses required to access certain third-party content).
"Researchers at more than 20 academic institutions in North America including Stanford, Harvard and the University of Chicago are currently using the DiscoveryGate platform to answer research questions—and more are expected by the end of the year," said Elsevier MDL President and CEO Lars Barfod. "Elsevier MDL appreciates the University of Wisconsin’s support of the growing DiscoveryGate community in North America."
DiscoveryGate for academia features a campus-wide access model. When an institution licenses DiscoveryGate, any number of eligible researchers at the institution may use the service—access is not limited to a few people at a time. To learn more about how DiscoveryGate helps academic researchers find the information they need, visit www.discoverygate.com, contact your Elsevier MDL Account Manager or request information at www.mdl.com.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services.Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+1 (925) 543-5400